{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:30:26Z","timestamp":1780623026954,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cardfail.2023.02.015","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:40:52Z","timestamp":1679445652000},"page":"818-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond Stage C: Considerations in the Management of Patients With Heart Failure Progression and Gaps in Evidence"],"prefix":"10.1016","volume":"29","author":[{"given":"AUBRIE M.","family":"CARROLL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARYJANE","family":"FARR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STUART D.","family":"RUSSELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KELLY H.","family":"SCHLENDORF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAUREN K.","family":"TRUBY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NISHA A.","family":"GILOTRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUSTIN M.","family":"VADER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHETAN B.","family":"PATEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-2221","authenticated-orcid":false,"given":"ADAM D.","family":"DEVORE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2023.02.015_bib0001","first-page":"00050","volume":"21","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0002","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 AHA\/ACC\/HFSA Guideline or the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"5","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamacardio.2021.4024","article-title":"Identifying treatments for stage C2 heart failure","volume":"7","author":"Yancy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0004","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the","volume":"6","author":"Heidenreich","year":"2013","journal-title":"American Heart Association. Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF Randomized Clinical Trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0007","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCHEARTFAILURE.121.009218","article-title":"Development of advanced heart failure: a population-based study","volume":"15","author":"Subramaniam","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0008","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.amjcard.2014.07.022","article-title":"Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing","volume":"114","author":"Patel","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0009","article-title":"Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels","year":"1953","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1067\/mhl.2002.124554","article-title":"Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease","volume":"31","author":"Bennett","year":"2002","journal-title":"Heart Lung"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF Trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0012","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores","volume":"66","author":"Simpson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.healun.2019.09.008","article-title":"Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): rationale, design, baseline characteristics, and inclusion criteria performance","volume":"39","author":"Aaronson","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.04.026","article-title":"Comparison of accuracy of estimation of cardiac output by thermodilution versus the fick method using measured oxygen uptake","volume":"176","author":"Narang","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction","volume":"77","author":"Maddoz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","article-title":"Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee","volume":"21","author":"Fang","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0017","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0019","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0021","first-page":"17","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"1","author":"Mann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(05)74355-5","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Dargie","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0023","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0024","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0026","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0027","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0028","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0029","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0031","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jchf.2018.03.019","article-title":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and metaanalysis","volume":"6","author":"Nizamic","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0032","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0033","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.mayocpiqo.2020.05.007","article-title":"Expected vs actual outcomes of elective initiation of inotropic therapy during heart failure hospitalization","volume":"4","author":"Snipelisky","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0034","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCHEARTFAILURE.114.001778","article-title":"Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure","volume":"8","author":"Hashim","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0035","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0036","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0037","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.108.793273","article-title":"Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial","volume":"119","author":"Anand","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0038","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.106.629261","article-title":"Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure","volume":"115","author":"Lindenfeld","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0039","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0040","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0041","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2020.12.047","article-title":"3-year outcomes of transcatheter mitral valve repair in patients with heart failure","volume":"77","author":"Mack","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0042","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.healun.2020.09.005","article-title":"MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry","volume":"39","author":"Godino","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0043","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0044","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jchf.2020.01.014","article-title":"Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches","volume":"8","author":"Truby","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0046","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0047","first-page":"29","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0048","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.cardfail.2017.07.032","article-title":"Map the gap: regional mapping to assess distribution of heart failure mortality and advanced heart failure treatment facilities","volume":"23","author":"Ahmad","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0049","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cardfail.2022.04.008","article-title":"The impact of health care disparities on patients with heart failure","volume":"28","author":"Morris","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0051","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0052","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0053","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine_isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0054","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine\u2013isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0056","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0057","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0058","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0059","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0061","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0062","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0063","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0064","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus lowdose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, doubleblind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.02.015_bib0065","first-page":"2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"ATLAS Study Group. Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:50:25Z","timestamp":1761029425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916423000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1071916423000787"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.015","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Stage C: Considerations in the Management of Patients With Heart Failure Progression and Gaps in Evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}